Flow Cytometry of Hematological Malignancies

Spis treści:
1. The Antigens
1.1 bcl–2 protein
General features
Cytometric features
Practical hints
1.2. CD1 antigens
1.3 CD2 antigens
1.4 CD3 antigens
1.5 CD4 antigens
1.6 CD5 antigens
1.7. CD7 antigen
1.8 CD8 antigen
1.9 CD10 antigen
1.10. CD11a antigen
1.11 CD11b antigen
1.12 CD11c antigen
1.13 CD13 antigen
1.14 CD14 antigen
1.15 CD15 antigen
1.16 CD16 antigen
1.17 CD19 antigen
1.18 CD20 antigen
1.19 CD22 antigen
1.20 CD23 antigen
1.21 CD24 antigen
1.22 CD25 antigen
1.23 CD26 antigen
1.24 CD27 antigen
1.28 CD30 antigen
1.29 CD33 antigen
1.30 CD34 antigen
1.31 CD38 antigen
1.32 CD43 antigen
1.33 CD45 antigen
1.34 CD45 isoforms
1.35 CD55 antigen
1.36 CD56 antigen
1.37 CD57 antigen
1.38 CD59 antigen
1.39 CD61 antigen
1.40 CD62L antigen
1.41 CD64 antigen
1.42 CD65 antigen
1.43 CD66 antigens
1.44 CD71 antigen
1.45 CD75 antigen
1.46 CD79 antigen
1.47 CD87 antigen
1.48 CD103 antigen
1.49 CD117 antigen
1.50 CD138 antigen
1.51 Cytotoxic proteins
1.52 HLA–DR antigen
1.53 Immunoglobulins
1.54 NG2 antigen
1.55 NK cell receptors
1.56 Peroxidases
1.57 T cell receptor
1.58 TdT (terminal deoxynucleotidyl transferase)
1.59 ZAP–70 protein
2. The Diseases
2.1 Acute leukaemias
2.1.1 Precursor B–cell neoplasms (B–ALL/LBL)
2.1.2 Precursor T–cell neoplasms (T–ALL/LBL)
2.1.3 Acute myeloid leukaemias (AML)
2.2 Myelodysplastic and myeloproliferative diseases
2.2.1 Myelodysplastic diseases (MDS)
2.2.2 Myeloproliferative diseases (CMPD)
2.2.3 Chronic myelomonocytic leukaemia (CMML)
2.2.4 Cytometric strategies
2.2.5 G–CSF therapy and iper–regenerative conditions
2.3 Mature B–cell neoplasms
2.3.1 B–cell chronic lymphocytic leukaemia (B–CLL)
2.3.2 B–cell prolymphocytic leukaemia (B̵ 1;PLL)
2.3.3 Lymphoplasmacytic lymphoma (LPL)
2.3.5 Marginal zone lymphoma (MZL)
2.3.6 Hairy cell leukaemia (HCL)
2.3.7 Mantle cell lymphoma (MCL) ..”
2.3.8 Burkitt lymphoma/Burkitt leukaemia (BL/B–ALL L3)
2.3.9 Follicular lymphoma (FL)
2.3.10 Diffuse large B–cell lymphoma (DLBCL)
2.3.11 Plasma cell neoplasms
2.4 Mature T– and NK–cell neoplasms
2.4.1 T–cell chronic lymphocytic leukaemia (T–CLL)
2.4.2 T–cell prolymphocytic lekaemia (T–PLL)
2.4.3 Mycosis fungoides/Sezary syndrome (MF/SS)
2.4.4 Lymphoproliferative disease of granular lymphocytes (LDGL)
2.4.5 Adult T–cell leukaemia/lymphoma (ATLL)
2.4.6 Enteropathy associated T–cell lymphoma (EATCL)
2.4.7 Hepatosplenic T–cell lymphoma (HSTCL)
2.4.8 Subcutaneous panniculitis–like T–cell lymphoma (SPTCL)
2.4.9 Anaplastic large cell lymphoma (ALCL)
2.4.10 Peripheral T–cell lymphoma, unspecified (PTCLnos)
2.4.11 Angioimmunoblastic T–cell lymphoma (AITL)
2.4.12 Aggressive NK–cell leukaemia (ANKL)
2.4.13 Extranodal NK/T lymphomas, “nasal–type” (ENKL)
2.4.14 Hypersensitivity to mosquito bites (HMB)
A.1 Appendix
A1.1 Paroxysmal nocturnal haemoglobinuria (PNH)
A1.2 Polyclonal lymphocytoses
A1.3 Acronyms
References